Advertisement
Journal of Investigative Dermatology Home

A Randomized Open Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation.

  • Michael S. Garshick
    Correspondence
    Corresponding author: Michael Garshick, MD Assistant Professor, Department of Medicine, NYU Langone Health (212) 263-0855, Center for the Prevention of Cardiovascular Disease, 435 East 30th Street, 7th Floor New York, NY 10016,
    Affiliations
    Center for the Prevention of Cardiovascular Disease, Department of Medicine, NYU Langone Health

    Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health

    Cardiovascular Research Center, NYU Langone Health
    Search for articles by this author
  • Kamelia Drenkova
    Affiliations
    Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health

    Cardiovascular Research Center, NYU Langone Health
    Search for articles by this author
  • Tessa J. Barrett
    Affiliations
    Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health

    Cardiovascular Research Center, NYU Langone Health
    Search for articles by this author
  • Florencia Schlamp
    Affiliations
    Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health

    Cardiovascular Research Center, NYU Langone Health
    Search for articles by this author
  • Edward A. Fisher
    Affiliations
    Center for the Prevention of Cardiovascular Disease, Department of Medicine, NYU Langone Health

    Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health

    Cardiovascular Research Center, NYU Langone Health
    Search for articles by this author
  • Stuart Katz
    Affiliations
    Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health
    Search for articles by this author
  • Sanja Jelic
    Affiliations
    Division of Pulmonary, Allergy & Critical Care Medicine, Department of Medicine, Columbia University Medical Center
    Search for articles by this author
  • Andrea L. Neimann
    Affiliations
    Ronald O. Perelman Department of Dermatology, NYU Langone Health
    Search for articles by this author
  • Jose U. Scher
    Affiliations
    Psoriatic Arthritis Center, Division of Rheumatology, Department of Medicine, NYU Langone Health
    Search for articles by this author
  • James Krueger
    Affiliations
    Laboratory for Investigative Dermatology, Rockefeller University
    Search for articles by this author
  • Jeffrey S. Berger
    Affiliations
    Center for the Prevention of Cardiovascular Disease, Department of Medicine, NYU Langone Health

    Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health

    Cardiovascular Research Center, NYU Langone Health

    Division of Hematology, Department of Medicine, NYU Langone Health

    Division of Vascular Surgery, Department of Surgery, NYU Langone Health
    Search for articles by this author
Published:November 18, 2021DOI:https://doi.org/10.1016/j.jid.2021.07.190
      In psoriasis, immune systemic activation and cardiometabolic abnormalities, including dyslipidemia, play a role in promoting impaired endothelial health and increased cardiovascular (CV) risk.(
      • Greb J.E.
      • Goldminz A.M.
      • Elder J.T.
      • Lebwohl M.G.
      • Gladman D.D.
      • Wu J.J.
      • et al.
      ) Psoriasis patients have elevated brachial vein endothelial pro-inflammatory transcript expression (impaired vascular endothelial health) with the degree of impairment directly correlated to skin activity and circulating biomarkers of systemic inflammation.(
      • Garshick M.S.
      • Barrett T.
      • Wechter T.
      • Azarchi S.
      • Scher J.
      • Neimann A.
      • et al.
      Inflammasome Signaling and Impaired Vascular Health in Psoriasis.
      ) In psoriasis, TNF and IL-17A synergism promote inflammasome (IL-1β) signaling and downstream IL-6 production (driver of C-reactive protein [CRP]), (
      • Verma D.
      • Fekri S.Z.
      • Sigurdardottir G.
      • Bivik Eding C.
      • Sandin C.
      • Enerback C.
      Enhanced Inflammasome Activity in Patients with Psoriasis Promotes Systemic Inflammation.
      ) which associates with vascular endothelial inflammatory transcript expression suggesting a pathogenic (immune-mediated) mechanism of atherosclerosis development.(
      • Garshick M.S.
      • Barrett T.
      • Wechter T.
      • Azarchi S.
      • Scher J.
      • Neimann A.
      • et al.
      Inflammasome Signaling and Impaired Vascular Health in Psoriasis.
      )

      Abbreviations:

      CVD (Cardiovascular disease), CV (Cardiovascular), LDL (low-density lipoprotein), IL (Interleukin), Hs-CRP (high-sensitivity C-reactive protein), NPX (Normalized protein eXpression), MeanEC (Mean expression of pro-inflammatory vascular endothelial transcripts), PASI (Psoriasis area and severity index), HDL-C (high density lipoprotein cholesterol), TNF (Tumor necrosis factor)
      To read this article in full you will need to make a payment
      Purchase one-time access
      Society Members (SID/ESDR), remember to log in for access.
      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Adhyaru B.B.
        • Jacobson T.A.
        Safety and efficacy of statin therapy.
        Nat Rev Cardiol. 2018; 15: 757-769
      1. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74(10):1376-1414.

        • Garshick M.
        • Underberg J.A.
        The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis.
        Curr Atheroscler Rep. 2017; 19: 48
        • Garshick M.S.
        • Barrett T.
        • Wechter T.
        • Azarchi S.
        • Scher J.
        • Neimann A.
        • et al.
        Inflammasome Signaling and Impaired Vascular Health in Psoriasis.
        Arterioscler Thromb Vasc Biol. 2019; (ATVBAHA118312246)
        • Garshick M.S.
        • Barrett T.J.
        • Wechter T.
        • Azarchi S.
        • Scher J.U.
        • Neimann A.
        • et al.
        Inflammasome Signaling and Impaired Vascular Health in Psoriasis.
        Arterioscler Thromb Vasc Biol. 2019; 39: 787-798
        • Garshick M.S.
        • Tawil M.
        • Barrett T.J.
        • Salud-Gnilo C.M.
        • Eppler M.
        • Lee A.
        • et al.
        Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1.
        Arterioscler Thromb Vasc Biol. 2020; 40: 1340-1351
        • Greb J.E.
        • Goldminz A.M.
        • Elder J.T.
        • Lebwohl M.G.
        • Gladman D.D.
        • Wu J.J.
        • et al.
        Psoriasis. Nat Rev Dis Primers. 2016; 2: 16082
        • Jelic S.
        • Lederer D.J.
        • Adams T.
        • Padeletti M.
        • Colombo P.C.
        • Factor P.H.
        • et al.
        Vascular inflammation in obesity and sleep apnea.
        Circulation. 2010; 121: 1014-1021
        • Kianifard F.
        • Islam M.Z.
        A guide to the design and analysis of small clinical studies.
        Pharm Stat. 2011; 10: 363-368
        • Michelson A.D.
        • Barnard M.R.
        • Krueger L.A.
        • Frelinger 3rd, A.L.
        • Furman M.I.
        Evaluation of platelet function by flow cytometry.
        Methods. 2000; 21: 259-270
        • Ports W.C.
        • Fayyad R.
        • DeMicco D.A.
        • Laskey R.
        • Wolk R.
        Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis.
        Clin Drug Investig. 2017; 37: 775-785
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • Genest J.
        • Gotto Jr., A.M.
        • Kastelein J.J.
        • et al.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Verma D.
        • Fekri S.Z.
        • Sigurdardottir G.
        • Bivik Eding C.
        • Sandin C.
        • Enerback C.
        Enhanced Inflammasome Activity in Patients with Psoriasis Promotes Systemic Inflammation.
        J Invest Dermatol. 2021; 141: 586-595 e5
        • Wu J.J.
        • Poon K.Y.
        • Channual J.C.
        • Shen A.Y.
        Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
        Arch Dermatol. 2012; 148: 1244-1250